Skip to main content
Home > The Daily Extra > Company News

Chronological Index of : Company News

 Current Issue
  • COMPANY NEWS: Ablynx: Merck Serono may unwind deal

    Ablynx N.V. (Euronext:ABLX) said during its 4Q14 earnings call that partner Merck Serono S.A. is likely to terminate a 2013 deal to develop Nanobodies against cancer, immunology and neurology targets. Ablynx did not …

    Published on 2/27/2015
  • COMPANY NEWS: AstraZeneca to spin out anti-infectives unit

    AstraZeneca plc (LSE:AZN; NYSE:AZN) said it will spin out its anti-infectives unit into a subsidiary company based in Waltham, Mass. AZ will invest $40 million in the subsidiary and expects it to be fully operational in…

    Published on 2/27/2015
  • COMPANY NEWS: Eddingpharm gains Chinese rights to Amarin's Vascepa

    Amarin Corp. plc (NASDAQ:AMRN) granted Eddingpharm Inc. (Shanghai, China) exclusive rights to hypertriglyceridemia drug Vascepa icosapent ethyl in Greater China.Amarin will receive $15 million up front and is eligible …

    Published on 2/27/2015
  • COMPANY NEWS: Sandoz fires back in Zarxio suit

    The Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) filed an opposition brief to a motion by Amgen Inc. (NASDAQ:AMGN) seeking a preliminary injunction that would prevent Sandoz from marketing Zarxio (EP2006), a …

    Published on 2/27/2015
  • COMPANY NEWS: TaiMed's ibalizumab gets breakthrough designation

    WuXi PharmaTech Inc. (NYSE:WX) said FDA granted breakthrough designation to ibalizumab (TMB-355) from its partner Taimed Biologics Inc. (GreTai:4147) to treat HIV.TaiMed has completed a Phase IIb trial of IV ibalizumab …

    Published on 2/27/2015
  • COMPANY NEWS: Management tracks

    Ophthalmology company Ohr Pharmaceutical Inc. (NASDAQ:OHRP) hired Avner Ingerman as chief clinical officer. Ingerman was formerly VP of ophthalmology at Regeneron Pharmaceuticals Inc. (NASDAQ:REGN). Cancer vaccine play …

    Published on 2/26/2015
  • COMPANY NEWS: Otonomy submits NDA for AuriPro

    Otonomy Inc. (NASDAQ:OTIC) submitted an NDA to FDA for AuriPro, a sustained-release gel formulation of ciprofloxacin, to treat middle ear effusion in pediatric patients requiring tympanostomy tube placement surgery.…

    Published on 2/26/2015
  • COMPANY NEWS: Pharmacyclics holds gains after takeout rumors

    Pharmacyclics Inc. (NASDAQ:PCYC) held onto most of Wednesday's gains on rumors that the biotech is considering takeout bids from Johnson & Johnson (NYSE:JNJ) and Novartis AG (NYSE:NVS; SIX:NOVN) in the range of $17-$18 …

    Published on 2/26/2015
  • COMPANY NEWS: After cuts, Pfizer looks to gene therapy, immuno-oncology

    Pfizer Inc. (NYSE:PFE) said it will cut an undisclosed number of R&D jobs at its Cambridge, Mass., and Collegeville, Pa., facilities. Pfizer spokesperson Dean Mastrojohn declined to say which R&D areas would be cut. The…

    Published on 2/25/2015
  • COMPANY NEWS: FDA delays meeting to discuss Remicade biosimilar

    FDA's Arthritis Advisory Committee postponed a meeting that had been scheduled for March 17 to discuss a BLA from Celltrion Inc. (KOSDAQ:068270) for CT-P13, a biosimilar of Remicade infliximab from Johnson & Johnson (…

    Published on 2/25/2015
  • COMPANY NEWS: G-BA backs J&J's Sylvant

    Germany's Federal Joint Committee (G-BA) concluded that Sylvant siltuximab from Johnson & Johnson (NYSE:JNJ) provides added benefit for patients with multicentric Castleman's disease (MCD) who are HIV-negative and human…

    Published on 2/25/2015
  • COMPANY NEWS: Management tracks

    GTx Inc. (NASDAQ:GTXI) hired Robert Wills as executive chairman and chair of its board's Scientific & Development Committee, effective March 2. Wills is retiring as vice president, alliance manager at Johnson & Johnson…

    Published on 2/25/2015
  • COMPANY NEWS: Alkermes discontinues pain candidate, reports earnings

    Alkermes plc (NASDAQ:ALKS) dipped $3 to $70.64 on Tuesday after it discontinued development of pain candidate ALKS 7106 and reported 4Q14 earnings.The company said results from a Phase I trial of ALKS 7106 did not meet …

    Published on 2/24/2015
  • COMPANY NEWS: Management tracks

    Tony Rosenberg, head of M&A and licensing at the Novartis International AG unit of Novartis AG (NYSE:NVS; SIX:NOVN), will retire on Feb. 28. Rosenberg managed the pending asset swap between Novartis and GlaxoSmithKline …

    Published on 2/24/2015
  • COMPANY NEWS: Shire exercises option to acquire Meritage

    Shire plc (LSE:SHP; NASDAQ:SHPG) exercised its option to acquire Meritage Pharma Inc. (San Diego, Calif.) for $70 million up front. Meritage is eligible for $175 million in milestones.The option was triggered by the …

    Published on 2/24/2015
  • COMPANY NEWS: BMS, Rigel in cancer immunotherapy deal

    Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) picked up $0.68 (27%) to $3.23 on Monday after it granted Bristol-Myers Squibb Co. (NYSE:BMY) exclusive, worldwide rights to develop cancer immunotherapies based on Rigel's small…

    Published on 2/23/2015
  • COMPANY NEWS: BMS to acquire Flexus for up to $1.3B

    Bristol-Myers Squibb Co. (NYSE:BMY) will acquire cancer immunotherapy play Flexus Biosciences Inc. (San Carlos, Calif.) for $800 million up front.BMS will receive Flexus' F001287, a preclinical small molecule inhibitor …

    Published on 2/23/2015
  • COMPANY NEWS: Celldex GBM vaccine gets breakthrough designation

    Celldex Therapeutics Inc. (NASDAQ:CLDX) jumped $3.52 (17%) to $24.73 on Monday after FDA granted breakthrough designation to Rintega rindopepimut (CDX-110) to treat adults with EGFR variant III (EGFRvIII)-positive …

    Published on 2/23/2015
  • COMPANY NEWS: Celltrion, Hospira avoid biosimilar traffic jam in U.S.

    With an FDA advisory committee meeting approaching on March 17 for CT-P13 from Celltrion Inc. (KOSDAQ:068270) and Hospira Inc. (NYSE:HSP), the partners' U.S. interests are aligned thanks to an amended deal that gives …

    Published on 2/23/2015
  • COMPANY NEWS: Merck, NGM partner on preclinical compounds

    Merck & Co. Inc. (NYSE:MRK) and NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) entered a five-year research collaboration that gives Merck options to license multiple preclinical candidates from NGM, …

    Published on 2/23/2015
  • COMPANY NEWS: PTC spikes on takeout rumors

    PTC Therapeutics Inc. (NASDAQ:PTCT) rose $9.77 (18%) to $64.96 on Monday on media reports that companies including BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Shire plc (LSE:SHP; NASDAQ:SHPG) are seeking to acquire …

    Published on 2/23/2015
  • COMPANY NEWS: Sosei to acquire Heptares for up to $400M

    Sosei Group Corp. (Tokyo:4565) will acquire Heptares Therapeutics Ltd. (Welwyn Garden City, U.K.) for $180 million up front and up to $220 million in milestones.Sosei will receive Heptares' StaR drug discovery platform …

    Published on 2/23/2015
  • COMPANY NEWS: Valeant to acquire Salix for $14.5B

    Valeant Pharmaceuticals International Inc. (TSX:RVX; NYSE:VRX) will acquire Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) for $158 per share, or $14.5 billion in cash.Salix markets a portfolio of gastrointestinal drugs …

    Published on 2/23/2015
  • COMPANY NEWS: Cerecor licenses KOR antagonist from Lilly

    Eli Lilly and Co. (NYSE:LLY) granted Cerecor Inc. (Baltimore, Md.) exclusive, worldwide rights to LY2456302, a kappa opioid receptor (KOR) (OPRK1) antagonist. Lilly previously developed the candidate to treat co-…

    Published on 2/20/2015
  • COMPANY NEWS: EC approves Chiesi's stem cells for the eye

    The European Commission granted conditional marketing authorization for Holoclar from Chiesi Farmaceutici S.p.A. (Parma, Italy) to treat adults with moderate to severe limbal stem cell deficiency (LSCD) due to physical …

    Published on 2/20/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993